Predictors of humoral response to SARS-CoV-2 mRNA vaccine BNT162b2 in patients receiving maintenance dialysis

• Egile Nagusiak: Tingting Li (Egilea), Sumanth Gandra (Egilea), Kimberly A. Reske (Egilea), Margaret A. Olsen (Egilea), Silvana Bommarito (Egilea), Candace Miller (Egilea), Karl G. Hock (Egilea), Claire A. Ballman (Egilea), Christina Su (Egilea), Na Le Dang (Egilea), Jennie H. Kwon (Egilea), David K. Warren (Egilea), Victoria J. Fraser (Egilea), Christopher W. Farnsworth (Egilea), for the Centers for Disease Control and Prevention Epicenters Program (Egilea)
• Formatua: Liburua
• Argitaratua: Cambridge University Press, 2022-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Objective: Patients on dialysis are at high risk for severe COVID-19 and associated morbidity and mortality. We examined the humoral response to SARS-CoV-2 mRNA vaccine BNT162b2 in a maintenance dialysis population. Design: Single-center cohort study. Setting and participants: Adult mainten...